Argenx
A Belgian biotechnology company focused on developing antibody therapies for autoimmune diseases.
Last updated August 20, 2026
Overview
Argenx is a Belgian biotechnology company founded in 2008 and headquartered in Ghent, Belgium. The company focuses on developing innovative antibody therapies for severe autoimmune diseases and cancer. Its lead product, efgartigimod (brand name Vyvgart), is approved for the treatment of myasthenia gravis. Argenx is listed on NASDAQ and Euronext Brussels.
Products and positioning
Innovative biotechnology company in immunology
Product categories. Efgartigimod (Vyvgart) · Other antibody-based therapies
Flagship businesses
- Vyvgart (efgartigimod)
Cite this profile: Cite the canonical profile. /brand-wiki/argenx · Editorial policy · How profiles are compiled